Tirzepatide structure: the dual-receptor design behind Mounjaro

The biggest misconception: tirzepatide is not just a stronger GLP-1 drug

Most people researching Mounjaro assume it works the same way as semaglutide, only at a higher potency. That is not quite right. Semaglutide activates a single receptor, GLP-1. Tirzepatide's molecular structure is built to bind two separate receptors: the glucose-dependent insulinotropic polypeptide receptor (GIP-R) and the glucagon-like peptide-1 receptor (GLP-1R). These are not redundant pathways. They work through different mechanisms in different tissues, and the combination produces effects that neither pathway generates alone.

The NHS's patient information on tirzepatide describes it as acting on both receptors to regulate appetite and blood-sugar levels. The practical result seen in trials (including SURMOUNT-1, published in the New England Journal of Medicine) was average body-weight reduction of around 20–21% at the 15 mg dose over 72 weeks, figures that outpaced anything previously reported for a single weekly injection in the licensed population. The structural reason matters here: a molecule that hits two receptors in a coordinated way can produce a different dose-response curve than simply turning one dial higher.

Understanding the full clinical profile of tirzepatide helps put those trial numbers in context, they reflect the combined receptor activity, not a simple amplification of the GLP-1 effect.

How the peptide is actually built

At the chemical level, tirzepatide is a 39-amino-acid synthetic peptide. Its backbone is derived from the native GIP hormone sequence, with modifications that introduce GLP-1 receptor binding activity. The molecule is acylated (a long fatty-acid chain is attached) which allows it to bind to albumin in the bloodstream and slow its clearance. That is why a single subcutaneous injection sustains activity across a full week.

This architecture is explored in more technical depth on our tirzepatide molecular structure page, and the specific chemistry of how Mounjaro is formulated as an injectable solution is covered in the Mounjaro chemical structure overview. What matters clinically is that the fatty-acid modification is not cosmetic: without it, the peptide would be cleared from the body within hours, making once-weekly dosing impossible.

The molecule arrives in a pre-filled KwikPen, each pen contains four weekly doses at the prescribed strength. If you are wondering whether the liquid you inject changes between strengths, it does not in structure; the tirzepatide pen guide explains how the device itself works. The pen your pharmacist dispatches is calibrated to the specific dose your prescriber has approved, so the structural molecule is constant from 2.5 mg through to 15 mg.

Why the GIP pathway matters, and what is still being studied

GIP receptors are found in fat tissue, the brain and the gut. When tirzepatide activates them alongside GLP-1 receptors, the combined effect appears to produce greater reductions in appetite and fat mass than GLP-1 activation alone. NICE's appraisal of tirzepatide (TA1026) noted that indirect comparisons across the clinical programme favoured tirzepatide over semaglutide 2.4 mg, a conclusion subsequently confirmed in the SURMOUNT-5 head-to-head trial.

What researchers are still unpicking is the precise contribution of the GIP arm to each downstream effect. Some evidence suggests GIP agonism helps reduce nausea, which would partly explain why tirzepatide's tolerability profile during dose escalation can differ from that of GLP-1-only medicines. These questions matter for future drug design, and if you want to explore how the licensed formulations differ, our guide to tirzepatide l covers the relevant distinctions in plain terms. For someone considering treatment today the practical point is that the dual-receptor structure is the approved, licensed mechanism behind Mounjaro as it currently exists.

If you are weighing up your options, the weight-loss treatments overview covers both Mounjaro and Wegovy side by side in plain terms. Cost context (including how UK private pricing has shifted since Eli Lilly's list-price change) is set out on the Lilly UK price increase page, which is worth reading before making any financial comparisons between providers.

What this means if you are thinking about treatment

Tirzepatide's structural complexity translates into a real-world clinical profile: dual-pathway appetite suppression, once-weekly dosing and a graduated dose schedule that starts at 2.5 mg to let your body adjust before the prescriber moves the dose up. That opening dose is not meant to produce substantial weight loss on its own; its job is to give your system time to settle before the therapeutic doses begin.

It is a prescription-only medicine. A prescriber reviews your health history, current medicines and BMI before deciding whether tirzepatide is appropriate and, if so, at which starting point. Our clinical team (led by a GPhC-registered Independent Prescriber) does that review the same day your consultation arrives, no algorithm in the loop. Once approved, treatment is dispatched from our pharmacy in plain, unbranded packaging; DPD sends you a tracking link so you know exactly when to expect it.

If you have questions about the process before starting, our FAQs cover the most common ones. When you are ready, start your free consultation and a real clinician will take it from there.